Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Endostar in Advanced Non-Small Cell Lung Cancer
ChiCTR2300079300Phase 2Completed
- Sponsor
- Mudanjiang Cancer Hospital
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and endostar in non-small cell lung cancer (NSCLC), sponsored by Mudanjiang Cancer Hospital. Primary endpoint: Objective Response Rate. Started Dec 2023; status: completed.
02
Drugs
camrelizumabendostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300079300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079300.